CF PharmTech (Stock Code: 02652) announced the submission of a marketing authorization application for CF017, a budesonide suspension for inhalation, to the drug regulatory authority of an unnamed Southeast Asian jurisdiction.

CF017 received approval from China’s National Medical Products Administration in May 2021 and is already commercialized domestically. Management highlights Southeast Asia’s large population, rising healthcare demand and increasing incidence of respiratory diseases as key drivers for expanding the product’s international footprint.

The company underscores that the filing represents an administrative step rather than final clearance; approval remains subject to regulatory review. Shareholders are cautioned about the inherent uncertainties of overseas pharmaceutical registration and commercialization.

CF PharmTech positions itself as an inhalation drug delivery specialist with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization. Its pipeline targets respiratory and nasal diseases and is extending into areas such as pulmonary fibrosis, pulmonary arterial hypertension and central nervous system disorders via nose-to-brain delivery platforms.

The board is chaired by Dr. Liang Bill Wenqing. The voluntary announcement was released in Hong Kong on 28 May 2026.